|
EP2784084B2
(en)
|
2003-07-08 |
2023-10-04 |
Novartis Pharma AG |
Antagonist antibodies to IL-17A/F heterologous polypeptides
|
|
CA2589746A1
(en)
*
|
2004-12-08 |
2006-06-15 |
Cedars-Sinai Medical Center |
Methods for diagnosis and treatment of crohn's disease
|
|
WO2008109782A2
(en)
*
|
2007-03-06 |
2008-09-12 |
Cedars-Sinai Medical Center |
Diagnosis of inflammatory bowel disease in children
|
|
US7790862B2
(en)
|
2006-06-13 |
2010-09-07 |
Zymogenetics, Inc. |
IL-17 and IL-23 antagonists and methods of using the same
|
|
US7910703B2
(en)
*
|
2006-03-10 |
2011-03-22 |
Zymogenetics, Inc. |
Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
|
|
EP2046835B1
(en)
|
2006-08-11 |
2011-10-26 |
Schering Corporation |
Antibodies to il-17a
|
|
US8414897B1
(en)
|
2006-10-02 |
2013-04-09 |
The Uab Research Foundation |
Pathway for Th-17 cell development and methods utilizing same
|
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Ｉｌ-２３拮抗劑於治療感染之用途
|
|
US20100021917A1
(en)
*
|
2007-02-14 |
2010-01-28 |
Cedars-Sinai Medical Center |
Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
|
|
ES2708988T3
(es)
|
2007-02-23 |
2019-04-12 |
Merck Sharp & Dohme |
Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
|
|
JP2010518858A
(ja)
*
|
2007-02-23 |
2010-06-03 |
シェーリング コーポレイション |
操作された抗−ｉｌ−２３ｐ１９抗体
|
|
US20100190162A1
(en)
*
|
2007-02-26 |
2010-07-29 |
Cedars-Sinai Medical Center |
Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
|
|
CA2679400A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Schering Corporation |
Combination therapy for treatment of immune disorders
|
|
WO2008137762A2
(en)
*
|
2007-05-04 |
2008-11-13 |
Cedars-Sinai Medical Center |
Methods of diagnosis and treatment of crohn's disease
|
|
WO2008106579A2
(en)
*
|
2007-02-28 |
2008-09-04 |
Cedars-Sinai Medical Center |
The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
|
|
WO2008116150A2
(en)
|
2007-03-21 |
2008-09-25 |
Cedars-Sinai Medical Center |
Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
|
|
WO2008134569A2
(en)
*
|
2007-04-26 |
2008-11-06 |
Cedars-Sinai Medical Center |
Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
|
|
EP2150564A2
(en)
|
2007-04-27 |
2010-02-10 |
ZymoGenetics, Inc. |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
|
US9305137B1
(en)
|
2007-05-18 |
2016-04-05 |
Cedars-Sinai Medical Center |
Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
|
|
EP2174667B1
(en)
*
|
2007-07-26 |
2017-01-04 |
Osaka University |
Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
|
|
US20100203009A1
(en)
*
|
2007-10-02 |
2010-08-12 |
The Uab Research Foundation |
Pathway for Th-17 Cell Development and Methods Utilizing Same
|
|
WO2009082624A2
(en)
*
|
2007-12-10 |
2009-07-02 |
Zymogenetics, Inc. |
Antagonists of il-17a, il-17f, and il-23 and methods of using the same
|
|
EP2604279A1
(en)
*
|
2008-03-27 |
2013-06-19 |
ZymoGenetics, Inc. |
Compositions and methods for inhibiting PDGFRBETA and VEGF-A
|
|
RU2474588C2
(ru)
|
2008-05-05 |
2013-02-10 |
Новиммун Са |
Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
|
|
UA112050C2
(uk)
*
|
2008-08-04 |
2016-07-25 |
БАЄР ХЕЛСКЕР ЛЛСі |
Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
|
|
WO2010019565A2
(en)
*
|
2008-08-12 |
2010-02-18 |
Medlmmune, Llc |
Anti-ephrin b2 antibodies and their use in treatment of disease
|
|
EP2331078B1
(en)
|
2008-08-27 |
2012-09-19 |
Merck Sharp & Dohme Corp. |
Lyophilized formulations of engineered anti-il-23p19 antibodies
|
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
|
US20110177969A1
(en)
*
|
2008-10-01 |
2011-07-21 |
Cedars-Sinai Medical Center |
The role of il17rd and the il23-1l17 pathway in crohn's disease
|
|
US20110189685A1
(en)
*
|
2008-10-22 |
2011-08-04 |
Cedars-Sinai Medical Center |
Methods of using jak3 genetic variants to diagnose and predict crohn's disease
|
|
SG2014006860A
(en)
*
|
2008-11-12 |
2014-05-29 |
Merck Sharp & Dohme |
ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
|
|
US20110223169A1
(en)
*
|
2008-11-26 |
2011-09-15 |
Stern Michael E |
Il-17 antibody inhibitor for treating dry eye
|
|
WO2010062857A1
(en)
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Klk-13 antibody inhibitor for treating dry eye
|
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
|
EP2379710A1
(en)
|
2008-12-19 |
2011-10-26 |
Schering Corporation |
Feed supplement for mammalian cell culture and methods of use
|
|
US9580752B2
(en)
|
2008-12-24 |
2017-02-28 |
Cedars-Sinai Medical Center |
Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
|
|
CN102458437B
(zh)
|
2009-05-05 |
2015-06-10 |
诺维莫尼公司 |
抗il-17f抗体及其使用方法
|
|
EP3366692A1
(en)
|
2009-06-22 |
2018-08-29 |
Amgen, Inc |
Refolding proteins using a chemically controlled redox state
|
|
AU2010266093B2
(en)
|
2009-06-25 |
2013-06-27 |
Amgen Inc. |
Capture purification processes for proteins expressed in a non-mammalian system
|
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
|
CA2774326C
(en)
|
2009-09-14 |
2023-11-07 |
Donald Bellgrau |
Modulation of yeast-based immunotherapy products and responses
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
EP2493506B1
(en)
|
2009-10-30 |
2019-04-10 |
Janssen Biotech, Inc. |
Il-17a antagonists
|
|
GB201013975D0
(en)
|
2010-08-20 |
2010-10-06 |
Imp Innovations Ltd |
Method of treating desease
|
|
US9045536B2
(en)
|
2009-12-23 |
2015-06-02 |
Merck Sharp & Dohme Corp. |
Cell line 3M
|
|
PT3345615T
(pt)
|
2010-03-01 |
2020-01-17 |
Bayer Healthcare Llc |
Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
|
|
WO2011119948A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
US20110311527A1
(en)
*
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
|
MX2019000046A
(es)
|
2010-11-04 |
2023-10-05 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-23.
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
RU2014100111A
(ru)
|
2011-06-10 |
2015-07-20 |
МЕДИММЬЮН, ЭлЭлСи |
МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
|
|
US8946150B2
(en)
|
2011-06-14 |
2015-02-03 |
Medical Diagnostic Laboratories, LLC. |
Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
|
|
USRE49026E1
(en)
|
2011-06-14 |
2022-04-12 |
Medical Diagnostic Laboratories, Llc |
Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
|
|
EP2583979B1
(en)
*
|
2011-10-19 |
2015-12-16 |
Effimune |
Methods to prepare antibodies directed against p19 subunit of human IL-23
|
|
HRP20201370T1
(hr)
|
2011-11-07 |
2020-11-27 |
Medimmune Limited |
Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
|
|
EP2809660B1
(en)
|
2012-02-02 |
2016-01-20 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for modulating il-17
|
|
PL3326649T3
(pl)
|
2012-05-03 |
2022-04-25 |
Boehringer Ingelheim International Gmbh |
Przeciwciała anty-il-23p19
|
|
US8945553B2
(en)
*
|
2012-05-22 |
2015-02-03 |
Bristol-Myers Squibb Company |
Bispecific antibodies to IL-23 and IL-17A/F
|
|
KR20150052808A
(ko)
*
|
2012-05-31 |
2015-05-14 |
에이전시 포 사이언스, 테크놀로지 앤드 리서치 |
단백질 제제 내에서 응집체 함량을 감소시키는 혼합된 다기능성 금속 친화성 표면들
|
|
ES2729603T3
(es)
|
2012-06-27 |
2019-11-05 |
Merck Sharp & Dohme |
Anticuerpos IL-23 antihumanos cristalinos
|
|
NZ630363A
(en)
|
2012-07-25 |
2018-09-28 |
Celldex Therapeutics Inc |
Anti-kit antibodies and uses thereof
|
|
EA039595B1
(ru)
*
|
2012-10-05 |
2022-02-15 |
Кадмон Корпорейшн, Ллк |
Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела
|
|
JP2016502502A
(ja)
*
|
2012-10-05 |
2016-01-28 |
カドモン コーポレイション，リミティド ライアビリティ カンパニー |
眼疾患の治療
|
|
US9273093B2
(en)
|
2012-10-11 |
2016-03-01 |
Protagonist Therapeutics, Inc. |
α4β7 peptide dimer antagonists
|
|
US10526384B2
(en)
|
2012-11-19 |
2020-01-07 |
Pieris Pharmaceuticals Gmbh |
Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
SG11201507482UA
(en)
|
2013-03-15 |
2015-10-29 |
Amgen Inc |
Methods for treating psoriasis using an anti-il-23 antibody
|
|
SG11201507483PA
(en)
|
2013-03-15 |
2015-10-29 |
Amgen Inc |
Methods for treating crohn's disease using an anti-il23 antibody
|
|
EP4091624A1
(en)
|
2013-03-15 |
2022-11-23 |
Protagonist Therapeutics, Inc. |
Hepcidin analogues and uses thereof
|
|
KR20230109779A
(ko)
|
2013-03-27 |
2023-07-20 |
세다르스-신나이 메디칼 센터 |
Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
|
|
EP3022295A4
(en)
|
2013-07-19 |
2017-03-01 |
Cedars-Sinai Medical Center |
Signature of tl1a (tnfsf15) signaling pathway
|
|
RU2577228C2
(ru)
*
|
2014-03-14 |
2016-03-10 |
Закрытое Акционерное Общество "Биокад" |
Анти-il-17-антитела, способ их получения и способ применения
|
|
HRP20211448T1
(hr)
|
2014-05-16 |
2021-12-24 |
Protagonist Therapeutics, Inc. |
Alfa4beta7 integrin tioeter peptidni antagonisti
|
|
WO2015177175A2
(en)
|
2014-05-22 |
2015-11-26 |
Pieris Ag |
Novel specific-binding polypeptides and uses thereof
|
|
CN113975386A
(zh)
|
2014-05-23 |
2022-01-28 |
塞尔德克斯医疗公司 |
嗜酸性粒细胞或肥大细胞相关病症的治疗
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
PE20170769A1
(es)
*
|
2014-07-14 |
2017-07-04 |
Gennova Biopharmaceuticals Ltd |
Procedimiento novedoso para la purificacion de rhu-gcsf
|
|
CN107206254B
(zh)
*
|
2014-07-17 |
2021-08-24 |
领导医疗有限公司 |
白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
|
|
EP3708679A1
(en)
|
2014-07-24 |
2020-09-16 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
|
EA202193002A2
(ru)
|
2014-09-03 |
2022-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Соединение, нацеленное на ил-23a и фно-альфа, и его применение
|
|
WO2016054411A1
(en)
|
2014-10-01 |
2016-04-07 |
Protagonist Therapeutics, Inc. |
NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
|
|
US10301371B2
(en)
|
2014-10-01 |
2019-05-28 |
Protagonist Therapeutics, Inc. |
Cyclic monomer and dimer peptides having integrin antagonist activity
|
|
AR102417A1
(es)
*
|
2014-11-05 |
2017-03-01 |
Lilly Co Eli |
Anticuerpos biespecíficos anti-tnf- / anti-il-23
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
AU2016215535B2
(en)
|
2015-02-04 |
2021-09-16 |
Boehringer Ingelheim International Gmbh |
Methods of treating inflammatory diseases
|
|
WO2016138312A2
(en)
*
|
2015-02-25 |
2016-09-01 |
Vanderbilt University |
Antibody-mediated neutralization of marburg virus
|
|
EP3265493B1
(en)
|
2015-03-02 |
2024-01-10 |
180 Therapeutics LP |
Method of treating a localized fibrotic disorder using an il-33 antagonist
|
|
KR20170135972A
(ko)
*
|
2015-04-14 |
2017-12-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
질환을 치료하는 방법
|
|
TW201702272A
(zh)
|
2015-05-22 |
2017-01-16 |
美國紀念斯隆 凱特琳癌症中心 |
Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
|
|
MA41010B1
(fr)
*
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
CN108290058B
(zh)
|
2015-09-17 |
2023-05-16 |
美国安进公司 |
使用il23途径生物标志物预测il23拮抗剂的临床应答
|
|
AU2016361462B2
(en)
*
|
2015-11-27 |
2023-09-21 |
Csl Limited |
CD131 binding proteins and uses thereof
|
|
US11220541B2
(en)
|
2015-12-22 |
2022-01-11 |
Amgen Inc. |
CCL20 as a predictor of clinical response to IL23-antagonists
|
|
US20190002503A1
(en)
|
2015-12-30 |
2019-01-03 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
|
KR20240095481A
(ko)
|
2016-03-17 |
2024-06-25 |
세다르스-신나이 메디칼 센터 |
Rnaset2를 통한 염증성 장 질환의 진단 방법
|
|
CA3017926C
(en)
|
2016-03-23 |
2023-10-10 |
Protagonist Therapeutics, Inc. |
Methods for synthesizing .alpha.4.beta.7 peptide antagonists
|
|
WO2017205820A1
(en)
*
|
2016-05-27 |
2017-11-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Affinity matured broad spectrum antibodies to hepatitis c virus
|
|
US9611297B1
(en)
*
|
2016-08-26 |
2017-04-04 |
Thrasos Therapeutics Inc. |
Compositions and methods for the treatment of cast nephropathy and related conditions
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
EP3681900A4
(en)
|
2017-09-11 |
2021-09-08 |
Protagonist Therapeutics, Inc. |
OPIOID AGONIST PEPTIDES AND THEIR USES
|
|
CA3089868A1
(en)
|
2018-02-08 |
2019-08-15 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
WO2019191563A1
(en)
*
|
2018-03-29 |
2019-10-03 |
Remd Biotherapeutics, Inc. |
Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
|
|
WO2020014646A1
(en)
|
2018-07-12 |
2020-01-16 |
Protagonist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
CN112689643A
(zh)
|
2018-07-13 |
2021-04-20 |
阿斯特捷利康合作创业有限责任公司 |
用布雷库单抗治疗溃疡性结肠炎
|
|
WO2020081408A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
MX2021004928A
(es)
|
2018-10-31 |
2021-06-08 |
Merck Sharp & Dohme Llc |
Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
JP7534382B2
(ja)
|
2019-07-10 |
2024-08-14 |
プロタゴニスト セラピューティクス， インコーポレイテッド |
インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
|
|
TW202535466A
(zh)
|
2019-09-09 |
2025-09-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-il-23p19抗體調配物
|
|
JP7758672B2
(ja)
|
2019-12-20 |
2025-10-22 |
ノヴァロック バイオセラピューティクス， リミテッド |
抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
|
|
AU2021209086A1
(en)
|
2020-01-15 |
2022-08-04 |
Janssen Biotech, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
CA3167751A1
(en)
|
2020-01-15 |
2021-07-22 |
Janssen Biotech, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US20220206001A1
(en)
*
|
2020-10-22 |
2022-06-30 |
Twist Bioscience Corporation |
Methods and systems for detecting coronavirus
|
|
JP7397239B2
(ja)
|
2020-11-20 |
2023-12-12 |
ヤンセン ファーマシューティカ エヌ．ベー． |
インターロイキン－２３受容体のペプチド阻害剤の組成物
|
|
EP4370146A4
(en)
|
2021-07-14 |
2025-05-21 |
Janssen Biotech, Inc. |
Lipidated peptide inhibitors of the interleukin-23 receptor
|
|
WO2023122211A2
(en)
*
|
2021-12-21 |
2023-06-29 |
Duke University |
Coronavirus antibodies and uses thereof
|
|
CN120826416A
(zh)
*
|
2022-12-02 |
2025-10-21 |
杰科生物医药公司 |
抗间皮素双特异性抗体及其使用方法
|
|
WO2025071335A1
(ko)
*
|
2023-09-27 |
2025-04-03 |
삼성바이오에피스 주식회사 |
항-il-17 항체의 안정한 액상 제형
|
|
WO2026058045A1
(en)
|
2024-09-12 |
2026-03-19 |
Takeda Pharmaceutical Company Limited |
Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
|